Numerous studies have identified distinct alterations in complement proteins and activation products in blood and/or CSF from AD patients compared with controls, or as predictors of progression to AD in individuals with mild cognitive impairment (MCI) (Table 2) [58–62]. This evidence concerns the gene VTN and Alzheimer disease.